Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid

N Kramer¹, G Müller¹, S Zierold¹, M Röckel², W Fröhlich², M Schefzyk³, J Kumbrink⁴, J C Hassel⁵, C Berking², M Ziemer⁶, D Nashan⁷, L E French^{1

8}, J Vera², K E Kerl-French¹, R Gutzmer⁹, L Heinzerling^{1

2}

Affiliations

¹ Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany.
² Department of Dermatology, Uniklinikum Erlangen, Comprehensive Cancer Center Erlangen - EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
³ Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
⁴ Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
⁵ Department of Dermatology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
⁶ Department of Dermatology, Allergology and Venerology, University Medical Center, Leipzig, Germany.
⁷ Department of Dermatology, Hospital Dortmund, Dortmund, Germany.
⁸ Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida, USA.
⁹ Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum Campus Minden, Minden, Germany.

N Kramer et al. J Eur Acad Dermatol Venereol. 2024 Aug.

. 2024 Aug;38(8):e722-e728.

doi: 10.1111/jdv.19860. Epub 2024 Feb 24.

¹ Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany.
² Department of Dermatology, Uniklinikum Erlangen, Comprehensive Cancer Center Erlangen - EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
³ Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
⁴ Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
⁵ Department of Dermatology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
⁶ Department of Dermatology, Allergology and Venerology, University Medical Center, Leipzig, Germany.
⁷ Department of Dermatology, Hospital Dortmund, Dortmund, Germany.
⁸ Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida, USA.
⁹ Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum Campus Minden, Minden, Germany.

No abstract available

References

1. Heinzerling L, de Toni EN, Schett G, Hundorfean G, Zimmer L. Checkpoint inhibitors. Dtsch Arztebl Int. 2019;116(8):119–126.
1. Kawsar A, Edwards C, Patel P, Heywood RM, Gupta A, Mann J, et al. Checkpoint inhibitor‐associated bullous cutaneous immune‐related adverse events: a multicentre observational study. Br J Dermatol. 2022;187:981–987.
1. Sadik CD, Langan EA, Gutzmer R, Fleischer MI, Loquai C, Reinhardt L, et al. Retrospective analysis of checkpoint inhibitor therapy‐associated cases of bullous pemphigoid from six German dermatology centers. Front Immunol. 2020;11:588582.
1. Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review. JAMA Dermatol. 2022;158(8):933–941.
1. Tsiogka A, Bauer JW, Patsatsi A. Bullous pemphigoid associated with anti‐programmed cell death protein 1 and anti‐programmed cell death ligand 1 therapy: a review of the literature. Acta Derm Venereol. 2021;101(1):1497.